By W. Orknarok. University of New Haven.
The co-administration of these drugs with CYP3A4 inhibitors in patients with severe malaria requires intensive monitoring order nolvadex 10 mg with amex, drug level monitoring (if possible) or an interruption of ART cheap nolvadex 10 mg line. Measles In 2002 nolvadex 20mg sale, more than 200 million annual cases of measles with about 600,000 deaths were reported by WHO. In HIV+ patients, measles have a higher morbidity and mortality. The virus is shed for prolonged periods of time (Moss 2002) which is especially problematic in Africa (Moss 2006). American studies show a mortality rate of 40%, mostly due to giant-cell pneumonitis (Kaplan 1996). Non-immune HIV+ patients should receive active or passive immunization before traveling to areas with a high prevalence of measles (see chapter on HIV and Vaccinations). Leishmaniasis Visceral leishmaniasis (kala azar) is a life-threatening opportunistic infection with limited therapeutic options (see chapter on AIDS). In German travelers, most infec- tions are acquired in Mediterranean countries. The infection is more frequent in HIV+ long-term travelers (Harms 2003, Weitzel 2005). Due to the infection’s poten- tially extended latency period, symptoms can occur long after exposure in endemic areas. Diagnosis is challenging, requiring cooperation with a specialized center. Severely immunocompromised HIV+ patients must be informed of the risk of leishmaniasis even when traveling to Mediterranean countries. Preventive measures against mosquito bites should be followed (see above); because of the vector’s small size, the use of impregnated mosquito nets of small mesh size is advisable. Cutaneous leishmaniasis does not seem to occur more frequently. In most tropical and subtropical regions, the risk of tuberculosis is higher than in Europe. Before and after long-term travel to such areas, it is advisable to determine the TB reactivity by interferon-gamma release assay (IGRA) of PPD skin test (Rieder 2001). Patients with a positive reaction or with a known high-risk exposure and no further signs of active tuberculosis should receive a course of treatment for latent tuberculosis (see chapter on Tuberculosis). HIV+ travelers should avoid risk areas such as hospitals, prisons or homeless shelters or wear adequate facemasks. Endemic mycoses Endemic mycoses outside endemic areas are rare. Nevertheless, they are able to cause life-threatening opportunistic infections in HIV+ patients even years after a stay in an endemic area. Most agents of endemic mycoses are thought to enter the pulmonary tract after inhalation of infective spores. In areas endemic for Penicillium marneffei (South East Asia, Southern China) and Coccidioides immitis (south-west parts of the USA, parts of Central and South America), increased exposure to dust or soil should be avoided (e. Histoplasma capsulatum is prevalent worldwide in soil contaminated with bird and bat droppings. Exposure might happen during eco- or adventure-tourism and should be avoided. Depending on the expected pathogen, either fluconazole or itracona- zole should be prescribed. Another fungus that can cause severe infections is Sporothrix schenkii. This pathogen, which occurs worldwide, enters the body through cutaneous lesions. Wearing gloves while working with plants, hay, or peat moss can reduce the sporotrichosis risk. Sexually transmitted diseases Traveling is associated with more frequent sexual encounters and less frequent use of condoms (Matteelli 2001). The risk of STDs is substantially increased (Richens 2006). Other parasites The following parasitic pathogens are relevant to HIV+ travelers: • Strongyloides stercoralis is prevalent in most tropical and subtropical areas. The par- asite is transmitted by cutaneous larval invasion after skin contact with contami- nated soil. In HIV+ patients, there is the risk of a “hyperinfection syndrome” with a high fatality rate (Gompels 1991). Corticosteroids seems to be an important risk factor, as they may increase larval maturation triggering a cycle of massive autoin- fection. The protozoon that causes Chagas disease is transmitted by triatomine bugs but oral transmissions via contaminated fruit or sugarcane juice have also been reported. Chagas disease can persist asymptomatically for many years and reactivate in severely immunocom- promised patients. In these cases, lesions radiologically resembling cerebral toxo- plasmosis are found in the central nervous system (Rocha 1994). Severe infections, clinically mimicking malaria or manifesting as fever of unknown origin, mainly occur in patients after splenectomy, but have also been reported in severely immunocompromised patients (Falagas 1996). Traveling with HIV 511 • Free-living amoeba (Acanthamoeba sp. In immunocompromised patients, these organisms are capable of causing severe infections of the central nervous system (granulomatous encephalitis) as well as local infections of the skin and cornea (Sison 1995). In HIV+ patients, schistosomiasis treatment is less effective (Kallestrup 2006). The chronic stimulation of the immune system has a negative influence on HIV infection (Secor 2006). HIV+ travelers should avoid freshwater contact in endemic areas. Medical problems after traveling Every disease occurring during or after traveling should be checked in a timely manner. Because most tropical diseases are quite rare in temperate countries, diag- nosis is often delayed. An analysis of imported visceral leishmaniasis in Germany revealed a median time span of 85 days until the diagnosis was established (Weitzel 2005). Furthermore, tropical diseases often manifest atypically (Karp 1999). In any event, differential diagnoses of diseases are very broad. After traveling abroad the clinical and diagnostic situation can become even more complex, calling for a close cooperation of HIV and Tropical Medicine specialists. Sexual transmission of intestinal parasites in men who have sex with men.
Studies on harms of statins in children Author buy nolvadex 10 mg mastercard, year How adverse events assessed Adverse events reported McCrindle buy nolvadex 10 mg fast delivery, 2003 AE reported by the subject or investigator were Atorvastatin vs placebo: recorded at each study visit and for up Safety AE: 62 order nolvadex 20 mg on line. Blood Laboratory abnormalities: 29% vs 34% pressure and pulse measured at each study visit, One discontinuation in atorva group due to increased depression. No clinically and a full physical exam at screening and weeks relevant changes in vital signs noted in either group. Stein, 1999 Laboratory measurements including ALT, AST, and Lovastatin had no significant effect on growth parameters at 24 and 48 weeks. Sexual maturation evaluated by Tanner More advanced Tanner staging and lager testicular volumes in lovastatin group, staging. Increase from baseline in ALT in both groups, no significant difference between groups (p=0. No clinically significant increase in transaminaes levels (>3 times ULN) or CK level (>10 times ULN). No differences between groups in clinical adverse events. Statins Page 388 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 11. Studies on harms of statins in children Author, year How adverse events assessed Adverse events reported Wiegman, 2004 Measured levels of sex steroids, gonadotopins, and No significant differences between pravastatin and placebo in change from variables of the pituitary-adrenal axis at baseline baseline in physical characteristics, liver and muscle enzymes, or hormones; no and at 1 and 2 years. Measurements of height, effect of pravastatin on academic performance. BMI, school records for education level and yearly progress, ALT, AST, adn CPK assessed at same time as lipids. Statins Page 389 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 12. Internal validity of trials evaluating statins in children Study or Author Randomization Allocation Eligibility criteria Outcome assessors Care provider Year adequate? Clauss et al, 2005 Yes Yes Drug estradiol 61 vs 95 for Yes Yes Not reported placebo Drug LDL 218 vs 199 Drug ApoB 187 vs 168 deJongh, 2002A Method not NR FH groups were similar Yes NR NR Early Statin Therapy described Restores… deJongh, 2002b Yes NR Yes Yes Described as NR "Efficacy and safety "double blind" of statin therapy…" Knipscheer, Method not NR Yes Yes Yes NR (n/a) 1996 described McCrindle, 2003 Method not NR Yes Yes Yes NR (n/a) described Statins Page 390 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 12. Internal validity of trials evaluating statins in children Patient Different or overall high Study or Author unaware of Intention-to-treat Maintained Reported attrition, crossovers, loss to follow- Year treatment? Internal validity of trials evaluating statins in children Study or Author Score Year Comments (good/ fair/ poor) Clauss et al, 2005 Good deJongh, 2002A Poor Early Statin Therapy Restores… deJongh, 2002b Good-Fair "Efficacy and safety of statin therapy…" Knipscheer, Fair 1996 McCrindle, 2003 Fair Statins Page 392 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 12. Internal validity of trials evaluating statins in children Study or Author Randomization Allocation Eligibility criteria Outcome assessors Care provider Year adequate? Stein, 1999 Method not NR Yes Yes Yes, "double blind" NR described van der Graaf A, et al Not described NR More mutiracial participants Yes Yes "double blind" NR 2008 in SIM monotherapy groups for steps 1 and 2 (pooled): 13 (10%) for EZE plus SIM groups vs. Wiegman, 2004 Yes Not reported Yes Yes Unclear, reported as NR (n/a) double-blind Statins Page 393 of 395 Final Report Update 5 Drug Effectiveness Review Project Evidence Table 12. Internal validity of trials evaluating statins in children Patient Different or overall high Study or Author unaware of Intention-to-treat Maintained Reported attrition, crossovers, loss to follow- Year treatment? Stein, 1999 Yes, "double blind" For safety; for Unclear Attrition reported 110/132 (83%) efficacy, those who No contamination reported completed Period 2. Wiegman, 2004 Yes, other than NR Yes Attrition reported. Internal validity of trials evaluating statins in children Study or Author Score Year Comments (good/ fair/ poor) Stein, 1999 Fair van der Graaf A, et al Randomzied to 6 arms Fair 2008 of varied doses for two treatment options (SIM alone vs EZE plus SIM), but analyzed in only two groups (lumped all doses together) Wiegman, 2004 Good-Fair Statins Page 395 of 395 . An evidence report also emphasizes measures that are easily interpreted in a clinical context. In general, measures of absolute risk or the probability of disease are preferred to measures such as relative risk. The difference in absolute risk between interventions depends on the numbers of events in both groups, such that the difference (absolute risk reduction) is smaller when there are fewer events. In contrast, the difference in relative risk is fairly constant across groups with different baseline risk for the event, such that the difference (relative risk reduction) is similar across these groups. Relative risk reduction is often more impressive than absolute risk reduction. Another measure useful in applying the results of a study is the number needed to treat (or harm). The number needed to treat represents the average number of patients who need to be treated with the intervention of interest in order to achieve 1 additional patient to benefit (that is, experience a positive outcome or avoid a negative outcome) relative to the comparator intervention. The absolute risk reduction is used to calculate the number needed to treat. Evidence reports also consider the quality of the evidence, giving more weight to studies that meet high methodological standards that reduce the likelihood of biased results. In general, for questions about the relative benefits of a drug, the results of well planned and executed randomized controlled trials are regarded as better evidence than results of cohort, case-control, or cross-sectional studies. In turn, these studies are considered better evidence than uncontrolled trials and case series. For questions about tolerability and harms, controlled trials typically provide limited information. For these questions, observational studies may provide important information that is not available from trials. Within this hierarchy, cohort designs are preferred when well conducted and assessing a common outcome. Case-control studies are preferred only when the outcome measure is rare and the study is well conducted. Evidence reports pay particular attention to the generalizability of results from efficacy studies performed in controlled or academic settings to “real world settings. However, the results of efficacy studies are often not applicable to many, and sometimes most, patients seen in everyday practice. This is because most efficacy studies use strict eligibility criteria that exclude patients based on their age, sex, medication adherence, or severity of illness. For many drug classes, including antipsychotics, unstable or severely impaired patients are often excluded from trials. Efficacy studies also often exclude patients who have comorbid diseases, meaning diseases other than the one under study. Efficacy studies may also use dosing regimens and follow-up protocols that Topical calcineurin inhibitors Page 5 of 74 Final Report Drug Effectiveness Review Project would be impractical in other practice settings. They often restrict options such as combining therapies or switching drugs that are of value in actual practice. And they often examine the short-term effects of drugs that in practice are used for much longer periods. Finally, efficacy studies tend to use objective measures of effects that do not capture all of the benefits and harms of a drug or do not reflect the outcomes that are most important to patients and their families. Evidence reports also highlight studies that reflect actual clinical effectiveness in unselected patients and community practice settings. Effectiveness studies conducted in primary care or office-based settings use less stringent eligibility criteria, assess more health outcomes, and have longer follow-up periods than most efficacy studies. The results of effectiveness studies are more applicable to the “average” patient than results from efficacy studies working with highly selected populations.
Sethi AK discount nolvadex american express, Celentano DD discount 10mg nolvadex overnight delivery, Gange SJ buy nolvadex with american express, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and HIV drug resistance. Slain D, Amsden JR, Khakoo RA, Effect of high-dose vitamin C on the steady-state pharmacokinetics of the pro- tease inhibitor indinavir in healthy volunteers. Waning of virological benefits following directly administered art among drug users: results from a randomized, controlled trial. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor- based antiretroviral regimens with or without concurrent ritonavir. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. Adherence to antiretroviral therapy by HIV-infected patients. The impact of adherence on CD4 cell count responses among HIV-infected patients. All combinations currently used as initial regimens consist of two NRTIs plus either a PI, an NNRTI or an integrase inhibitor. Advantages and problems of these three strategies are outlined in Table 6. There are considerable differences between these strategies with respect to pill burden, food restrictions, side effects, resistance risk, drug interactions and the amount of available data in special patient populations. A third NRTI (triple nuke) is only used in exceptional cases and is only briefly men- tioned here. All other combinations such as NRTI-free regimens or dual therapies are currently (January 2015) not justified for use outside the framework of clinical studies. Large, sufficiently powered, randomized studies directly comparing these different strategies are listed in Table 6. It is obvious that the amount of data differs from agent to agent. Efavirenz-based regimens were the comparator arm in many studies. On the other hand, for nevirapine and especially for rilpivirine, data derived from class-comparing studies is much more limited. With regard to PIs, most studies were performed with atazanavir/r and darunavir/r. Lopinavir/r was mainly used in resource-poor settings. Some of these studies are also shown in the table as they may be relevant in special settings. In contrast, the validity of previous milestone trials such as Atlantic (van Leeuwen 2003) is considered limited today due to outdated combinations and are not mentioned here. In most of the trials, the antiviral potency of the regimens was comparable, meas- ured by the number of patients with viral load below the limit of detection. Although there were considerable differences with regard to tolerability and the rate of resist- ance mutations, these studies do not provide enough evidence to compromise one of the three drug classes. Note: The MERIT study is not mentioned here, as mara- viroc is not licensed for first-line therapy in Europe 188 ART NNRTIs versus PI/s In ACTG 5142, an advantage of efavirenz over lopinavir/r was observed after 96 weeks (12% more patients got to below 50 copies/ml). However, if ART failed, resist- ance was less frequent and CD4 T cells increased more in the LPV/r arm. The ACTG 5142 trial showed that NNRTIs were possibly more effective than boosted PIs, because they were better tolerated. Resistance, however, occurs faster on NNRTIs than on PIs, which is probably due to the low resistance barrier. This phenomenon was observed in trials such as FIRST, ARTEN and ACTG 5202 (Gardner 2008, Daar 2011, Soriano 2011). These observations were confirmed in a systematic evaluation of 20 studies that included 7,949 patients (see Table 6. All of the patients had been treated with either an NNRTI or a boosted PI, and had additionally received 3TC or FTC. Virologic failure was as frequent on NNRTIs as on PIs (4. However, major differences were observed in patients with virologic failure whose genotypic resistance testing was successful. This applied for NRTI key mutations like the M184V and K65R, and also for other resistance mutations. All three integrase inhibitors were better tolerated. More patients discontinued efavirenz, mainly due to CNS toxicity. In FLAMINGO, GS103 and ACTG 5257, the integrase inhibitors were also tested against boosted PIs such as atazanavir/r or darunavir/r (Clotet 2014, Clumeck 2014, Lennox 2014). Dolutegravir und raltegravir were superior, mainly with regard to tolerability. It is important to consider, however, that tolerability depends on the specific setting and context of each study. During recent years, a switch to another regimen has become easier. The growing repertoire of antiviral agents implicates that the “toler- ance threshold” of both patients and their physicians declines. Especially the toler- ability of efavirenz has been reduced during recent years – in SINGLE, around 10% of all patients discontinued efavirenz due to CNS toxicity. These high rates have not been observed in older studies. So what about resistance-associated virological failure in these studies, the most rel- evant endpoint? Data suggest that resistance-associated mutations (RAMs) are less frequently seen with raltegravir and elvitegravir (1–2%) than with NNRTIs (1–9%). In ACTG 5257 (ARDENT), a three- armed trial, raltegravir was superior to both PIs, mainly due to better tolerability, but there were more RAMs (18/603 = 3%) seen with the integrase inhibitor (Lennox 2014). With dolutegravir, however, no RAMs were seen in all clinical trials, suggest- ing that the resistance barrier of this compound is as high as that of boosted PIs. In the FLAMINGO trial, not a single RAM was detected in any of the patients failing on dolutegravir or darunavir/r – a first in HIV therapy (Clotet 2014). What to start with 189 Thus, the pros and cons for the different strategies continue, and controversy over the best first-line therapy persists. One should be warned against cross-trial com- parisons, which are often used as marketing strategies to influence health providers on the effectiveness of a specific treatment (“we achieved over 90% tolerance rates in our study”).
Empiric TB therapy does not decrease early mortality compared to isoniazid preventive therapy in adults with advanced HIV initiating ART: results of ACTG A5274 (REMEMBER study) buy nolvadex 20mg free shipping. Human immunodeficiency virus associated tuberculosis more often due to recent infection than reactivation of latent infection 20mg nolvadex mastercard. Comparison of molecular and immunological methods for the rapid diagno- sis of smear-negative tuberculosis 20 mg nolvadex with visa. Int J Tuberc Lung Dis 2013, 17:1459-65 Jong E, Conradie F, Berhanu R, et al. Consensus statement: Management of drug-induced liver injury in HIV-pos- itive patients treated for TB. The risks of concurrent treatment with tenofovir and aminoglyco- sides in patients with HIV-associated tuberculosis. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Kitahata MM, Gange SJ, Abraham AG, et al Effect of early versus deferred antiretroviral therapy for HIV on sur- vival. N Engl J Med 2009; 360: 1815-26 Lange C, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. Management of patients with multidrug-resistant/extensively drug-resis- tant tuberculosis in Europe: a TBNET consensus statement. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons. Respirology 2013, 18:912-22 Leidl L, Mayanja-Kizza H, Sotgiu G, et al. Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. LTBI: latent tuberculosis infection or lasting immune response to Mycobacterium tuberculosis. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitu-tion inflammatory syndrome. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. Bronchoscopy in the human immunodeficiency virus-infected patient. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents Last updated April 8 2015. HOPE fixation: a novel fixing method and paraffin-embedding tech- nique for human soft tissues. Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay-A Clinical Validation Study. Clinical, immunological, and epidemiological importance of antituber- culosis T cell responses in HIV-infected Africans. Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. HIV-Mycobacterium tuberculosis co-infection: a ‘danger-couple model’ of disease pathogenesis. Clinical management of tuberculosis and HIV-1 co-infection. Eur Respir J 2010, 36:1460-81 Sester M, van Leth F, Bruchfeld J, et al. The risk of tuberculosis in immunocompromized hosts. Am J Respir Crit Care Med 2015; 190:1168-76 Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuber- culin skin test in HIV-infected individuals from a low prevalence tuberculosis country. Three months of rifapentine and isoniazid for latent tuberculosis infec- tion. Opportunistic Infections (OIs) 367 Swaminathan S, Padmapriyadarsini C, Narendran G. Clin Infect Dis 2010, 50:1377-86 Theron G, Peter J, van Zyl-Smit R,et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)—associated tuberculous meningitis. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. WHO 2011: Guidelines for the programmatic management of drug- resistant tuberculosis, update 2011. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance. The use of delamid in the treatment of multidrug-resistant tuberculosis: interim policyguidance. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Risk factors for developing tuberculosis in HIV-1-infected adults from com- munities with a low or very high incidence of tuberculosis. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. Although MAC is by far the most frequent pathogen, numerous other atypical mycobacterioses exist that cause a similar disease pattern, such as M. MAC bacteria are ubiqui- tous and can be found in diverse animal species, on land, in water and in food.
Pulmonary hypertension in sickle cell Conﬂict-of-interest disclosures: K purchase nolvadex 10 mg with mastercard. Quest Pharmaceuticals buy nolvadex online now, Sangart nolvadex 20 mg overnight delivery, and Selexys Pharmaceuticals; has 19. A hemodynamic study of pulmonary received research funding from HemaQuest Pharmaceuticals and hypertension in sickle cell disease. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Selexys Pharmaceuticals; has consulted for Pﬁzer and Celgene; and Pulmonary hypertension diagnosed by right heart catheterisation in has received honoraria from Pﬁzer, Adventrx Pharmaceuticals, sickle cell disease. Hemodynamic predictors of mortality has consulted for Pﬁzer. Off-label drug use: Prostacyclins and in adults with sickle cell disease. Deﬁnitions and diagnosis Correspondence of pulmonary hypertension. Pulmonary artery occlusion pressure University of North Carolina at Chapel Hill, Physicians’ Ofﬁce rd may overdiagnose pulmonary artery hypertension in sickle cell disease. Systemic fat embolism and pulmonary hypertension in sickle References cell disease. Pulmonary arterial pulmonary hypertension in Africa: a global perspective and review of hypertension and left-sided heart disease in sickle cell disease: clinical epidemiology, pathophysiology, and management. American Society of Echocardiography endorsed by the European 2010;376(9757):2018-2031. Association of Echocardiography, a registered branch of the European 4. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved Society of Cardiology, and the Canadian Society of Echocardiography. Survival of children with sickle natriuretic peptide levels and risk of death in sickle cell disease. Machado RF, Hildesheim M, Mendelsohn L, Remaley AT, Kato GJ, patients with sickle cell syndromes: results of a 17-year, single-center Gladwin MT. NT-pro brain natriuretic peptide levels and the risk of trial (LaSHS). Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in 2011;154(4):512-520. Pulmonary hypertension in patients lactic transfusions used to prevent stroke in sickle cell disease. N Engl with sickle cell disease: a longitudinal study. De Castro LM, Jonassaint JC, Graham FL, Ashley-Koch A, Telen MJ. Exercise capacity and transfusion lowers plasma free hemoglobin in children with sickle-cell haemodynamics in patients with sickle cell disease with pulmonary disease at risk for stroke. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: severe sickle cell phenotype. Burlington, MA: Jones and Bartlett Publishers; 2008;411-440. Pulmonary hypertension, tricuspid regurgitant velocity with sickle cell disease and pulmonary hypertension. Hagar RW, Michlitsch JG, Gardner J, Vichinsky EP, Morris CR. Prospective echocardiography with sickle cell disease. Pulmonary hypertension children with sickle cell disease. Pulmonary hypertension in sickle children with sickle cell disease. Pashankar FD, Carbonella J, Bazzy-Asaad A, Friedman A. Lee MT, Small T, Khan MA, Rosenzweig EB, Barst RJ, Brittenham follow up of elevated pulmonary artery pressures in children with sickle GM. Doppler-deﬁned pulmonary hypertension and the risk of death in cell disease. Elevated tricuspid disease during treatment with hydroxyurea. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Longitudinal study of echocardiog- to 9 years of treatment. Fitzgerald M, Fagan K, Herbert DE, Al-Ali M, Mugal M, Haynes J Jr. Misclassiﬁcation of pulmonary hypertension in adults with sickle 44. The effect of prolonged hemoglobinopathies using Doppler echocardiography. Ataga1,2 1Division of Hematology/Oncology and 2Comprehensive Sickle Cell Program, Department of Medicine, University of North Carolina, Chapel Hill, NC A 27-year-old man with sickle cell disease (HbSS) presents to the sickle cell clinic for follow-up after a screening echocardiogram revealed an increased tricuspid regurgitant velocity of 2. He has a history of 2 painful crises per year and has been hospitalized 3 times over the past 10 years for management of painful crises. He had one episode of acute chest syndrome at age 15 that was treated with an RBC exchange transfusion, supplemental oxygen, and intravenous antibiotics; he did not require mechanical ventilation. He has not had additional episodes of acute chest syndrome and does not have a history of stroke, retinopathy, or leg ulcers. The patient has never been treated with hydroxyurea. He wants to know whether hydroxyurea will prevent future pulmonary complications related to sickle cell disease. We Introduction then restricted the search to include only articles with “acute chest Hydroxyurea (HU) gained approval for the treatment of adults with syndrome” OR “pulmonary” as text words (Figure 1). We reviewed sickle cell anemia from the US Food and Drug Administration in the abstracts of each of these studies and excluded publications that 1998. The positive clinical effects of HU are thought to be largely did not evaluate and report the relationship between HU and acute mediated by the medication’s ability to induce the expression of chest syndrome or PH/increased TRV in at least 2 patients with fetal hemoglobin (HbF) in RBCs; low levels of HbF are one of the HbSS disease or HbS 0-thalassemia. We then reviewed the full strongest predictors of morbidity and mortality in sickle cell disease texts of the remaining articles and excluded additional studies based (SCD).
9 of 10 - Review by W. Orknarok
Votes: 63 votes
Total customer reviews: 63